CLINICAL ROLE -
Teclistamab-cqyv Shows Promise in Relapsed/Refractory Multiple Myeloma Following 4 Prior Lines of Therapy
Because of CRS and neurologic toxicity risk, the therapy is available through a REMS program.
Read More